10-K Decoder · All companies

Stoke Therapeutics, Inc.

STOK · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$184M$36.5M+405%
Operating income−$20.6M−$101M+79.7%
Net income−$6.88M−$89.0M+92.3%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 3, 2026

$Q3 2026Year earlierChange
Revenue$11.3M$10.6M+6.6%
Operating income−$77.3M−$43.1M−79.4%
Net income−$73.6M−$38.3M−92.2%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Stoke Therapeutics's revenue in FY2025?
$184M in FY2025 (Fiscal year ended Dec 31, 2025), +405% vs $36.5M a year earlier, per its 10-K filed Mar 2026.
Was Stoke Therapeutics profitable in FY2025?
No: net income was −$6.88M and operating income −$20.6M in FY2025.
What was Stoke Therapeutics's revenue in Q3 2026?
$11.3M (+6.6% vs a year earlier), per its Form 10-Q filed Nov 3, 2026.